1/9
12:22 pm
spry
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating [Yahoo! Finance]
Low
Report
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating [Yahoo! Finance]
12/30
08:12 am
spry
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg [Yahoo! Finance]
12/29
08:12 am
spry
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]
Low
Report
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]
12/29
08:00 am
spry
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
Low
Report
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
12/1
01:35 am
spry
How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]
Low
Report
How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]
11/26
08:28 am
spry
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
08:00 am
spry
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Low
Report
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
11/22
07:57 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/16
10:26 pm
spry
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks [Yahoo! Finance]
High
Report
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks [Yahoo! Finance]
11/10
04:41 pm
spry
ARS Pharma SPRY Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
ARS Pharma SPRY Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/10
02:04 pm
spry
ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating [Seeking Alpha]
Medium
Report
ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating [Seeking Alpha]
11/10
06:11 am
spry
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) [Yahoo! Finance]
11/10
06:08 am
spry
ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M [Seeking Alpha]
Low
Report
ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M [Seeking Alpha]
11/10
06:00 am
spry
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
Low
Report
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
11/4
09:04 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) is now covered by analysts at Roth Capital. They set a "buy" rating and a $30.00 price target on the stock.
Low
Report
ARS Pharmaceuticals (NASDAQ:SPRY) is now covered by analysts at Roth Capital. They set a "buy" rating and a $30.00 price target on the stock.
11/4
08:00 am
spry
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
Low
Report
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
11/3
02:23 pm
spry
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Low
Report
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
11/3
08:00 am
spry
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
Medium
Report
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
11/3
07:45 am
spry
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Medium
Report
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
10/24
05:33 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.